Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Stem cells have been investigated as a therapeutic option for hepatitis, particularly chronic liver diseases such as hepatitis B and C, which can lead to liver fibrosis and cirrhosis. The scientific rationale is based on the regenerative capacity of certain types of stem cells, including mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs), which have shown potential to differentiate into hepatocyte-like cells and modulate immune responses. Preclinical studies and early-phase clinical trials suggest that stem cell therapy may improve liver function, reduce fibrosis, and enhance tissue regeneration in patients with hepatitis-induced liver damage. For example, some clinical trials have reported improved liver enzyme profiles and histological findings after MSC transplantation in patients with liver failure secondary to hepatitis. However, the evidence is still preliminary, with most studies being small, non-randomized, or lacking long-term follow-up. There are also concerns about the safety, standardization, and optimal delivery methods of stem cell therapies. As of now, stem cells are not a standard treatment for hepatitis but are considered an experimental approach under clinical investigation. Larger, well-controlled trials are needed to confirm efficacy, determine optimal protocols, and establish safety profiles. Thus, while there is scientific interest and some early evidence, stem cell therapy for hepatitis remains in the investigational stage.

More about Stem Cells
More about Hepatitis

Other ingredients used for Hepatitis

Other health conditions supported by Stem Cells

Products containing Stem Cells